Skip to main content
Toggle navigation
Login
Search
Home
Conference Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
N
Na, Joo Young
The Ohio State University
(
W-087
)
Comparison of empirical and physiologically-based modeling approaches to explore mechanisms of drug-drug interaction between abemaciclib and olaparib in a small cohort of patients with ovarian cancer
Joo Young Na
Favorite
Nakayama, Shinji
mitsubishi tanabe pharma corporation
(
M-080
)
Development of a Simeprevir PBPK Model to Describe Changes in Coproporphyrin-I, an Endogenous OATP1B Biomarker, in Subjects with HCV
Shinji Nakayama
Favorite
Nazari, Fereshteh
(
T-088
)
A Computational Modeling Framework to Provide a Feasibility Assessment, Inform Competitor Differentiation Strategy, Best-in-Class Properties, and Target Selection for Biologics Targeting IBD
Fereshteh Nazari
Favorite
Neumar, Christine
Certara USA, Inc.
(
T-089
)
Integrated Population Pharmacokinetic Model of Bemnifosbuvir and Metabolites
Christine Neumar
Favorite
Ng, Chee Meng
NewGround Pharmaceutical Consulting LLC
(
T-090
)
Whole-body Two-pore PBPK Model to Investigate the Disposition of Immunoglobulin M (IgM) in Mice
Chee Meng Ng
Favorite
(
T-091
)
Fast Stepwise Selection Methods for Efficient Covariate Model Development in Population Data Analysis
Chee Meng Ng
Favorite
Nguyen, Hoa
Neurocrine Biosciences, Inc.
(
M-081
)
Population Pharmacokinetic and Exposure-Response Analyses of Valbenazine in Patients with Huntington’s Disease Chorea
Hoa Nguyen
Favorite
Nie, Jing
(
M-082
)
Integration of pharmacokinetics, safety, and efficacy into model-informed dose selection for Pimicotinib
Jing Nie
Favorite
Nieves, Emily
MIT, Delineate
(
T-092
)
Delineate: a Literature Co-Pilot for Quantitative Systems Pharmacology
Emily Nieves
Favorite
Nikfar, Mehdi
Genmab
(
M-083
)
Assessing Parameter Impacts on ADC Efficacy and Toxicity: Capabilities and Limitations of Sensitivity Analysis in an Innovative Full Physiologically Based Pharmacokinetic Pharmacodynamic Framework
Mehdi Nikfar
Favorite
Niloy, Kumar Kulldeep
Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital
(
T-093
)
Preclinical tumor growth inhibition modeling and simulation to support dosing regimen selection of a novel EWS-FLI1 inhibitor for Ewing sarcoma treatment
Kumar Kulldeep Niloy
Favorite
